Wells Fargo upgraded RxSight (RXST) to Overweight from Equal Weight with a price target of $25, up from $17.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Strategic Growth and International Expansion Drive Buy Rating
- RxSight: Favorable Risk/Reward Scenario with Strong Growth Prospects and Attractive Valuation
- RxSight’s Hold Rating: Balancing Strong Gross Margins and Macroeconomic Pressures with Promising Business Models
- RxSight, Inc. Reports Strong Q1 2025 Revenue Growth
- RxSight reports Q1 adjusted EPS (3c), consensus (8c)